Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
Rhea-AI Summary
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on Thursday, March 5, 2026 at 4:30 p.m. ET to report fourth quarter and full year results for the period ended December 31, 2025, and to provide a business update.
Participants may register for the call, join via telephone using conference ID 10206566, or listen on the company's Investor Relations website at ir.ateapharma.com. An archive of the webcast will be posted about two hours after the call and remain available for at least 90 days.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
AVIR was down 0.65% while peers showed mixed moves (e.g., IVVD up about 0.59%, OMER down about 1.9%), suggesting stock-specific trading rather than a unified sector move.
Previous Conferences,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Q3 2025 call notice | Neutral | +0.9% | Scheduled Q3 2025 results and business update conference call. |
| Jul 31 | Q2 2025 call notice | Neutral | -0.8% | Announced timing and access details for Q2 2025 earnings call. |
| Feb 27 | FY 2024 call notice | Neutral | -3.2% | Scheduled Q4 and full-year 2024 financial results conference call. |
| Oct 31 | Q3 2024 call notice | Neutral | -1.2% | Set date for Q3 2024 earnings call and webcast details. |
| Jul 31 | Q2 2024 call notice | Neutral | +0.0% | Announced Q2 2024 results call with business update and replay. |
Earnings/conference call scheduling headlines have historically led to modest moves, averaging about -0.85%, with reactions generally aligned with the neutral tone of such updates.
Over the past two years, Atea has repeatedly issued conferences,earnings notices for quarterly and annual results, typically scheduling calls at 4:30 p.m. ET and offering webcasts and archived replays. These announcements on Jul 31, 2024, Oct 31, 2024, Feb 27, 2025, Jul 31, 2025, and Nov 5, 2025 produced small share price moves around zero. Today’s notice follows the same pattern of routine pre-earnings communication and access details for investors.
Historical Comparison
Over the last five conferences,earnings notices, AVIR’s average move was -0.85%, indicating that scheduling earnings calls has typically led to only modest share price reactions.
The company has maintained a consistent cadence of quarterly and annual earnings call announcements from 2024 through 2025, each combining financial results timing with a business update and webcast access.
Market Pulse Summary
This announcement schedules Atea’s fourth quarter and full year 2025 results call for March 5, 2026 at 4:30 p.m. ET, continuing its regular disclosure cadence. Historical conferences,earnings notices have produced small moves, averaging about -0.85%. Investors may focus on updated cash, R&D spending, and progress in late-stage antiviral programs when results are released, using the webcast and 90-day replay to review management’s commentary in detail.
AI-generated analysis. Not financial advice.
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 5, 2026, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2025, and to provide a business update.
To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.ateapharma.com. To participate via telephone, please dial 1-877-300-8521 (U.S.) or 1-412-317-6026 (International) and use conference ID number 10206566. An archive of the audio webcast will be available on Atea’s website approximately two hours after the conference call and will remain available for at least 90 days following the event.
About Atea Pharmaceuticals
Atea is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Atea’s Phase 3 program is evaluating the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. Atea anticipates advancing AT-587, a nucleotide analog, for the treatment of HEV into Phase 1 after completion of first-in-human enabling studies. For more information, please visit www.ateapharma.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the Company’s plans relating to the date and time of the anticipated conference call and audio webcast. When used herein, words including “may,” “will,” “anticipates,” “plans,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements including those related to Atea’s plans to continue to build its pipeline of antiviral product candidates and advance AT-587 into Phase 1 after completion of first-in-human enabling studies are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, the important factors discussed and updated from time to time under the caption “Risk Factors” in the reports the Company files with the SEC, including annual reports on Form10-K, quarterly reports on Form10-Q, current reports on Form 8-K and other filings each of which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contacts
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
When will Atea Pharmaceuticals (AVIR) hold its Q4 and full-year 2025 results call?
How can investors access the Atea (AVIR) March 5, 2026 conference call and webcast?
Will Atea (AVIR) provide a replay of the March 5, 2026 earnings webcast and for how long?
What topics will Atea Pharmaceuticals (AVIR) cover during the March 5, 2026 business update?
What telephone numbers should participants use to join the Atea (AVIR) March 5, 2026 call?
